. . . . . . . . . "\"Ranolazine extended-release tablets are contraindicated in patients: Taking strong inhibitors of CYP3A [see Drug Interactions ( 7.1 Taking inducers of CYP3A [see Drug Interactions ( 7.1 With liver cirrhosis [see Use in Specific Populations (8.6 Strong CYP3A inhibitors (e.g., ketoconazole, clarithromycin, nelfinavir) ( 4 7.1 CYP3A inducers (e.g., rifampin, phenobarbital, St. John's wort) ( 4 7.1 Liver cirrhosis ( 4 8.6\"" . . . . . "RSA" . "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB" . "RzRl7mbDvqHf3HtxKDRXvcJ+l3XabsARSjAznksBJMucsRdUhKy8GT6jWYcw1Kcq4GxnmErkuUHpS/D56eSqkTxy2JiAi/3wYlQbeA2rQdmoSvNGEN9nGDuzG1Z+w9iNoQeaJtgXjBG2CoPWoS0b0GSvVTVOaZTlD+quarok9iU=" . . "2021-08-25T14:30:46.148+02:00"^^ . . . . .